Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inclacumab in sickle cell disease
2020-005289-32Phase 3Completed
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inclacumab in sickle cell disease (SCD), sponsored by Global Blood Therapeutics, Inc. Primary endpoint: Long-term safety of inclacumab. Started Jun 2021; status: completed.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2020-005289-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005289-32.